Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States.
Weill Cornell Medicine , New York , New York 10065 , United States.
ACS Sens. 2018 Sep 28;3(9):1838-1845. doi: 10.1021/acssensors.8b00631. Epub 2018 Aug 31.
Therapeutic outcomes in patients with prostate cancer are hindered by the inability to discern indolent versus aggressive disease. To address this problem, we developed a quantitative fluorescent nanosensor for the cancer biomarker urokinase plasminogen activator (uPA). We used the unique fluorescent characteristics of single-walled carbon nanotubes (SWCNT) to engineer an optical sensor that responds to uPA via optical bandgap modulation in complex protein environments. The sensing characteristics of this construct were modulated by passivation of the hydrophobic SWCNT surface with bovine serum albumin (BSA). The sensor enabled quantitative detection of known uPA concentrations in human blood products. These experiments potentiate future use of this technology as a rapid, point-of-care sensor for biomarker measurements in patient fluid samples. We expect that further work will develop a method to discern aggressive vs indolent prostate cancer and reduce overtreatment of this disease.
前列腺癌患者的治疗效果受到无法区分惰性与侵袭性疾病的阻碍。为了解决这个问题，我们开发了一种用于癌症生物标志物尿激酶型纤溶酶原激活物（uPA）的定量荧光纳米传感器。我们利用单壁碳纳米管（SWCNT）的独特荧光特性，通过在复杂的蛋白质环境中通过光学带隙调制来设计一种对 uPA 做出响应的光学传感器。该结构的传感特性通过用牛血清白蛋白（BSA）对疏水的 SWCNT 表面进行钝化来调节。该传感器能够对人血液制品中的已知 uPA 浓度进行定量检测。这些实验为将来将这项技术作为用于患者体液样本中生物标志物测量的快速即时护理传感器进行了铺垫。我们预计，进一步的工作将开发一种区分侵袭性和惰性前列腺癌的方法，并减少这种疾病的过度治疗。
